AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M
Benzinga
04-02
Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.
The Company continues to expect Med Device net sales to be flat.
The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.
The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.